Aclaris Therapeutics, Inc. (NASDAQ:ACRS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The firm presently has a $31.00 price target on the biotechnology company’s stock. Zacks Investment Research‘s price objective would suggest a potential upside of 14.69% from the stock’s current price.

According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “

A number of other research analysts have also weighed in on the company. Cantor Fitzgerald started coverage on Aclaris Therapeutics in a report on Friday, June 16th. They set an “overweight” rating and a $50.00 price objective on the stock. Jefferies Group LLC reaffirmed a “buy” rating and set a $36.00 price objective on shares of Aclaris Therapeutics in a report on Wednesday, June 28th. Guggenheim reaffirmed a “buy” rating and set a $40.00 price objective on shares of Aclaris Therapeutics in a report on Tuesday, July 4th. ValuEngine raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Finally, BidaskClub raised Aclaris Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, July 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $39.20.

Aclaris Therapeutics (NASDAQ ACRS) traded down 2.77% during midday trading on Tuesday, reaching $27.03. 523,264 shares of the company were exchanged. The company’s market capitalization is $722.67 million. Aclaris Therapeutics has a 52-week low of $20.15 and a 52-week high of $33.25. The company has a 50 day moving average of $26.00 and a 200-day moving average of $27.15.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.12. On average, equities research analysts anticipate that Aclaris Therapeutics will post ($3.10) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Aclaris Therapeutics, Inc. (ACRS) Stock Rating Upgraded by Zacks Investment Research” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/10/10/aclaris-therapeutics-inc-acrs-stock-rating-upgraded-by-zacks-investment-research.html.

In other news, Director Andrew N. Schiff bought 108,601 shares of the stock in a transaction on Wednesday, August 16th. The shares were bought at an average price of $23.02 per share, with a total value of $2,499,995.02. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 16.30% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of ACRS. Teachers Advisors LLC grew its holdings in Aclaris Therapeutics by 24.9% in the fourth quarter. Teachers Advisors LLC now owns 17,249 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 3,435 shares during the last quarter. Nationwide Fund Advisors boosted its stake in shares of Aclaris Therapeutics by 8.3% during the first quarter. Nationwide Fund Advisors now owns 6,627 shares of the biotechnology company’s stock valued at $198,000 after acquiring an additional 510 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Aclaris Therapeutics by 91.3% during the first quarter. Wells Fargo & Company MN now owns 12,359 shares of the biotechnology company’s stock valued at $369,000 after acquiring an additional 5,900 shares during the last quarter. Parametric Portfolio Associates LLC boosted its stake in shares of Aclaris Therapeutics by 67.0% during the first quarter. Parametric Portfolio Associates LLC now owns 55,397 shares of the biotechnology company’s stock valued at $1,652,000 after acquiring an additional 22,223 shares during the last quarter. Finally, Trexquant Investment LP acquired a new stake in shares of Aclaris Therapeutics during the first quarter valued at $201,000. 95.85% of the stock is currently owned by institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.